Teva and H. Lundbeck said that Azilect met its primary endpoint in the ANDANTE (Add oN to Dopamine AgoNists in the TrEatment of Parkinson’s disease) study, which was conducted to evaluate the efficacy ...

Patient Share of Teva/Lundbeck’s Azilect among Recently Treated Parkinson’s Disease Patients Grew 8 Percent Year over Year Decision Resources, one of the world’s leading research and advisory firms ...

Azilect (rasagiline) can cause side effects that range from mild to serious. More common side effects include headache and joint pain. If side effects become difficult to tolerate, talk with your ...

The price of one of the most commonly prescribed treatments for Parkinson’s disease has surged more than 200 percent over the past decade. That’s making the drug, Teva Pharmaceutical’s Azilect, ...

JERUSALEM & VALBY, Denmark--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect ® (rasagiline ...

Teva Pharmaceuticals announced that the FDA has approved revised Prescribing Information for Azilect (rasagiline tablets) reducing medication and food restrictions. The new labeling reflects reduced ...

Teva Pharmaceutical Industries and Lundbeck have presented new data from a late-stage trial of Azilect which suggest that the already-marketed drug could become the first disease-modifying treatment ...

Teva Announces First Patient Enrolled in Largest Clinical Study to Date Evaluating AZILECT®for Mild Cognitive Impairment in Parkinson's Disease "Cognitive impairment in PD is a major cause of ...

JERUSALEM, May 17 (UPI) -- Israeli firm Teva said Wednesday it has U.S. approval to market Azilect for Parkinson's disease. The drug maker said the Food and Drug Administration has cleared its ...

Teva Pharmaceutical Industries' bid to get expanded approval for its Parkinson's disease drug Azilect has been dealt a crushing blow by advisors to the US Food and Drug Administration. Teva ...

Surveyed Neurologists and PCPs Vary in Their Prescribing Patterns of Levodopa/Carbidopa and Dopamine Agonists, According to a New Report from Decision Resources WALTHAM, Mass., March 4 /PRNewswire/ -- ...

DUBLIN--(BUSINESS WIRE)--The "Azilect" report has been added to Research and Markets' offering. Azilect (Teva) is a pure isomer of rasagiline and is the most recent selective irreversible monoamine ...